How does tobramycin inhalation actually kill Pseudomonas aeruginosa in my lungs?
Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes (the protein-making factories inside germs) and shuts down their ability to build new proteins, causing the bacteria to die. When inhaled directly into the lungs, tobramycin reaches high local concentrations—up to 100× higher than oral antibiotics—making it far more lethal to P. aeruginosa biofilms [1][9].
Clinical trials show tobramycin inhalation reduces sputum P. aeruginosa density by 50% and improves lung function (FEV₁) by 26–35% within 24 weeks [1]. In cystic fibrosis patients using alternating 28-day on/off cycles, bacterial resistance stays low and lung decline slows dramatically [4][7]. The FDA approved this route specifically because swallowed tobramycin doesn't reach lung tissue in high enough doses to work [9].
Inside your lungs, tobramycin molecules cross the bacterial cell wall and jam up the ribosome—the machine that reads bacterial DNA and builds proteins. Without new proteins, the germ can't repair itself, divide, or survive. This mechanism works against most gram-negative rods, including tough biofilm-forming P. aeruginosa [1].
The trade-off: inhaled tobramycin stays mostly in the lungs (low systemic absorption), so kidney and hearing damage are rare but still possible with long-term use [9]. That's why baseline and annual audiograms and kidney function tests matter. Alternating tobramycin with other inhaled antibiotics (like aztreonam) every 28 days prevents resistance and keeps the drug effective for years [7][8].
Ask your pulmonologist: 'Should I start with tobramycin or try aztreonam first?' Alternating from day one prevents resistance better than using one drug continuously. Also confirm your baseline hearing and kidney function before your first dose [7].